(Reuters) -Eli Lilly and Co said on Friday it will acquire privately held drug developer Versanis for up to $1.93 billion, in a bid to boost its portfolio of obesity drugs.
Under the terms of the agreement, Versanis shareholders could receive $1.93 billion in cash, which includes an upfront payment and subsequent payments upon achievement of certain development and sales milestones.
Versanis’s lead drug, bimagrumab, is being evaluated in a mid-stage trial alone as well as in combination with Novo Nordisk (NYSE:)’s Wegovy or semaglutide in adults who are overweight or obese.
Freshworks Inc, the Chennai/ US-based provider AI service software, reported reduced net loss of $21…
Nifty 50 Today Live Updates on February 12, 2025: At 08:30 Nifty 50 was trading…
Elon Musk’s methodology at SpaceX can best be summed up in his acronym for a…
Bank Nifty Today Live Updates on February 12, 2025: At 08:30 Bank Nifty was trading…
Gift Nifty at 23,200 indicates a gap-up opening of about 50 points for Nifty. However,…
Your editorial “Britain should be bolder with its EU reset” (FT View, February 7) is…